FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200329038> ?p ?o ?g. }

• W4200329038 endingPage "S202" @default.
• W4200329038 startingPage "S201" @default.
• W4200329038 abstract "Abstract Background The preferred antibiotic salvage regimen for persistent methicillin-resistant Staphylococcus aureus bacteremia (pMRSAB) is unclear. Vancomycin plus ceftaroline (V/C) has demonstrated potent in vitro synergistic activity against MRSA; however, clinical data is limited. Thus, we sought to evaluate V/C salvage therapy for pMRSAB. Methods This was a single-center, retrospective cohort study of patients with MRSAB who received V/C salvage therapy between 1/1/2016-3/10/2021. Adult patients were included if blood cultures (BC) were positive for MRSA for ≥ 72 hours, received anti-MRSA monotherapy initially, and subsequently received V/C ≥ 24 hours. Patients were excluded if they received other anti-MRSA antibiotics within 72 hours of V/C initiation. The primary outcome was time to BC clearance following V/C initiation. Secondary outcomes included 90-day all-cause mortality, microbiological cure, 90-day MRSAB recurrence, and length of stay (LOS). Microbiological cure was defined as BC clearance. Results Of 178 patients identified, 20 were evaluated after inclusion and exclusion criteria were applied. Mean (SD) age and Pitt Bacteremia score were 38.5 (14.5) years and 4.2 (3.1), respectively. Most patients were male (70%), intravenous drug users (65%), and admitted to the intensive care unit (65%). The most common source was intravenous drug use (55%) and the majority had infective endocarditis (70%). All patients received infectious disease consultation and median (IQR) vancomycin AUC:MIC was 527 (454, 611). Source control, if possible, was obtained in most patients (55%). Median (IQR) time to bloodstream clearance from first positive BC and from when ceftaroline was initiated was 9.7 (8.4, 10.2) and 2.4 (1.5, 3.1) days, respectively. 90-day all-cause mortality, microbiological cure, and 90-day MRSAB recurrence occurred in 35%, 95%, and 5% of patients, respectively. Median (IQR) LOS was 25 (14.5, 32.0) days. Conclusion To our knowledge, this is the largest cohort to evaluate V/C for pMRSAB. Patients were medically complex; however, median time to MRSAB clearance following ceftaroline initiation was &lt; 2.5 days and microbiological cure was obtained in nearly all patients. V/C may represent a potential salvage regimen for pMRSAB. Disclosures Wesley D. Kufel, PharmD, Melinta (Research Grant or Support)Merck (Research Grant or Support)Theratechnologies, Inc. (Advisor or Review Panel member) Jeffrey Steele, Pharm.D., Paratek Pharmaceuticals (Advisor or Review Panel member)" @default.
• W4200329038 created "2021-12-31" @default.
• W4200329038 creator A5035450235 @default.
• W4200329038 creator A5037653066 @default.
• W4200329038 creator A5040605612 @default.
• W4200329038 creator A5049379142 @default.
• W4200329038 creator A5059606373 @default.
• W4200329038 creator A5069197284 @default.
• W4200329038 date "2021-11-01" @default.
• W4200329038 modified "2023-10-03" @default.
• W4200329038 title "187. Vancomycin Plus Ceftaroline Salvage Therapy for Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia" @default.
• W4200329038 doi "https://doi.org/10.1093/ofid/ofab466.389" @default.
• W4200329038 hasPublicationYear "2021" @default.
• W4200329038 type Work @default.
• W4200329038 citedByCount "0" @default.
• W4200329038 crossrefType "journal-article" @default.
• W4200329038 hasAuthorship W4200329038A5035450235 @default.
• W4200329038 hasAuthorship W4200329038A5037653066 @default.
• W4200329038 hasAuthorship W4200329038A5040605612 @default.
• W4200329038 hasAuthorship W4200329038A5049379142 @default.
• W4200329038 hasAuthorship W4200329038A5059606373 @default.
• W4200329038 hasAuthorship W4200329038A5069197284 @default.
• W4200329038 hasBestOaLocation W42003290381 @default.
• W4200329038 hasConcept C126322002 @default.
• W4200329038 hasConcept C141071460 @default.
• W4200329038 hasConcept C167135981 @default.
• W4200329038 hasConcept C2775872228 @default.
• W4200329038 hasConcept C2776694085 @default.
• W4200329038 hasConcept C2777052132 @default.
• W4200329038 hasConcept C2777334864 @default.
• W4200329038 hasConcept C2778651397 @default.
• W4200329038 hasConcept C2778980435 @default.
• W4200329038 hasConcept C2779443120 @default.
• W4200329038 hasConcept C2779489039 @default.
• W4200329038 hasConcept C2780176578 @default.
• W4200329038 hasConcept C2780775027 @default.
• W4200329038 hasConcept C2781413609 @default.
• W4200329038 hasConcept C501593827 @default.
• W4200329038 hasConcept C523546767 @default.
• W4200329038 hasConcept C54355233 @default.
• W4200329038 hasConcept C71924100 @default.
• W4200329038 hasConcept C86803240 @default.
• W4200329038 hasConcept C89423630 @default.
• W4200329038 hasConceptScore W4200329038C126322002 @default.
• W4200329038 hasConceptScore W4200329038C141071460 @default.
• W4200329038 hasConceptScore W4200329038C167135981 @default.
• W4200329038 hasConceptScore W4200329038C2775872228 @default.
• W4200329038 hasConceptScore W4200329038C2776694085 @default.
• W4200329038 hasConceptScore W4200329038C2777052132 @default.
• W4200329038 hasConceptScore W4200329038C2777334864 @default.
• W4200329038 hasConceptScore W4200329038C2778651397 @default.
• W4200329038 hasConceptScore W4200329038C2778980435 @default.
• W4200329038 hasConceptScore W4200329038C2779443120 @default.
• W4200329038 hasConceptScore W4200329038C2779489039 @default.
• W4200329038 hasConceptScore W4200329038C2780176578 @default.
• W4200329038 hasConceptScore W4200329038C2780775027 @default.
• W4200329038 hasConceptScore W4200329038C2781413609 @default.
• W4200329038 hasConceptScore W4200329038C501593827 @default.
• W4200329038 hasConceptScore W4200329038C523546767 @default.
• W4200329038 hasConceptScore W4200329038C54355233 @default.
• W4200329038 hasConceptScore W4200329038C71924100 @default.
• W4200329038 hasConceptScore W4200329038C86803240 @default.
• W4200329038 hasConceptScore W4200329038C89423630 @default.
• W4200329038 hasIssue "Supplement_1" @default.
• W4200329038 hasLocation W42003290381 @default.
• W4200329038 hasLocation W42003290382 @default.
• W4200329038 hasOpenAccess W4200329038 @default.
• W4200329038 hasPrimaryLocation W42003290381 @default.
• W4200329038 hasRelatedWork W1979569779 @default.
• W4200329038 hasRelatedWork W1986990242 @default.
• W4200329038 hasRelatedWork W2037240849 @default.
• W4200329038 hasRelatedWork W2046084936 @default.
• W4200329038 hasRelatedWork W2061663421 @default.
• W4200329038 hasRelatedWork W2124285733 @default.
• W4200329038 hasRelatedWork W2141365771 @default.
• W4200329038 hasRelatedWork W2150339728 @default.
• W4200329038 hasRelatedWork W2155139966 @default.
• W4200329038 hasRelatedWork W4200329038 @default.
• W4200329038 hasVolume "8" @default.
• W4200329038 isParatext "false" @default.
• W4200329038 isRetracted "false" @default.
• W4200329038 workType "article" @default.